Home Daily Intelligence Tracker
    • Plans Blog Contact
    Omnicell Inc logo
    OMCL

    Omnicell Inc

    MaveScore 31 Low model confidence
    Last Price US$44.91 As of Jul 10, 2026
    DCF Fair Price US$27.65 Research estimate · Jul 10, 2026 -39.3% vs price
    Market Cap US$2.0b Company size context
    7D Performance 4.37% Past 7 days
    1Y Performance 50.81% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Mar 31, 2026

    103 days old

    Market price date

    Jul 10, 2026

    2 days old

    Coverage

    16/16

    No missing model inputs

    Data quality

    Excellent

    Current stored snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 31 Low confidence

    Stored data quality

    Freshness and coverage checks

    16/16 Current stored snapshot

    Quality

    13/35 Weak

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    5/25 Weak

    Rewards durable profitability, margins, and positive free cash flow.

    Valuation Support

    5/15 Weak

    Favors positive earnings, positive cash flow, and lower multiples.

    Momentum

    8/15 Mixed

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    0/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Blends latest model rank with profitability and dilution ranks.
    • Rewards durable profitability, margins, and positive free cash flow.
    • Favors positive earnings, positive cash flow, and lower multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Omnicell Inc Overview

    Industry: Health Information Services

    Sector: Healthcare

    Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Santa Clara, California. Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the Read More

    Omnicell Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    Omnicell Inc

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Apr 28, 2026

    Quarterly result summary

    Revenue was $310M (reported); EPS was $0.4 (reported).

    Revenue $310M reported
    EPS $0.4 reported
    Net income/share $45,943 reported
    Operating income $31.2M +235% YoY

    What changed

    • Revenue reported to $310M; EPS reported to $0.4.
    • Operating income +235% YoY to $31.2M.

    Guidance / outlook

    we expect to incur expenses similar to certain of the non-GAAP adjustments described above and expect to continue reporting non-GAAP financial measures excluding such items.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q May 06, 2026 SEC filing 8-K Apr 28, 2026 SEC filing 10-K Feb 26, 2026 Earnings release Earnings release Feb 05, 2026 SEC filing 8-K Feb 05, 2026 SEC filing 10-Q Nov 05, 2025 Earnings release Earnings release Oct 30, 2025 SEC filing 8-K Oct 30, 2025 SEC filing 10-Q Aug 06, 2025 Earnings release Earnings release Jul 31, 2025 SEC filing 8-K Jul 31, 2025

    Recent News



    Earnings Per Share

    Score 2.00/5
    Omnicell Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Health Information Services industry , National Research Corp , HealthStream Inc , VEEVA SYSTEMS INC are companies with high ratings.

    Return on Equity

    Score 3.13/5
    Omnicell Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Omnicell Inc OMCL US$2.0b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 3.45/5
    Omnicell Inc commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Omnicell Inc OMCL US$2.0b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Health Information Services industry , National Research Corp , HealthStream Inc , VEEVA SYSTEMS INC are companies with high ratings.

    Leverage

    Score 2.11/5
    Omnicell Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Omnicell Inc OMCL US$2.0b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Omnicell Inc logo

    Omnicell Inc

    US$44.91

    US$27.65

    -39.3% vs price

    US$2.0b

    4.37%

    50.81%